ArticleFrontiers in veterinary science2020
Characteristics of Extended-Spectrum β-Lactamase-Producing
Article in Frontiers in veterinary science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 18 citations in OpenAlex.
- Extended-Spectrum β-Lactamase-ProducingAnimals : an open access journal from MDPI · 2026Article
- Article
- IncN-R plasmid co-integration contributing to extensive drug resistance inMicrobiology spectrum · 2025Article
- UropathogenicMicroorganisms · 2025Article
- Article
- Companions in antimicrobial resistance: examining transmission of common antimicrobial-resistant organisms between people and their dogs, cats, and horses.Clinical microbiology reviews · 2025Review
- Phenotypic and Molecular Characterization of Extended-Spectrum β-Lactamase, Plasmid-Mediated- AmpC, and Carbapenemase-Producing Enterobacteriaceae Isolated from Companion and Production Animals in Brazil.Current microbiology · 2025Article
- Genotyping of extended-spectrum beta-lactamase-producingVeterinary world · 2025Article
- Antimicrobial resistance patterns of multidrug resistant ESBL-producingIranian journal of veterinary research · 2025Article
- WGS of intrauterinemBio · 2024Article
- Antimicrobial Resistance and Biofilm Formation ofMicroorganisms · 2023Article
- Fecal Shedding of Multidrug ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Epidemiology of extended-spectrum β-lactamases inFrontiers in microbiology · 2022Review
- Presence of the Extended-Spectrum-β-Lactamase and Plasmid-Mediated AmpC-Encoding Genes inAntibiotics (Basel, Switzerland) · 2021Article
- Multiple and High-Risk Clones of Extended-Spectrum Cephalosporin-Resistant andAntibiotics (Basel, Switzerland) · 2021Article
- Prevalence of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Antibiotic-ResistantMicroorganisms · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended-spectrum β-lactamases (ESBLs) are enzymes that mediate resistance to newer β-lactam antibiotics, including extended-spectrum cephalosporins and monobactams. The production of ESBL is primarily plasmid mediated, and such plasmids often comprise the genes that encode resistance to other classes of antimicrobials, such as aminoglycosides and fluoroquinolones. Therefore, ESBL-producing microorganisms leave clinicians with limited therapeutic options in both human and veterinary medicine. Compared with human medicine, information regarding ESBL-producing microorganisms is limited in veterinary medicine. We screened for ESBL-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.